OncoMatch/Clinical Trials/NCT03007030
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
Is NCT03007030 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Brentuximab Vedotin for cd30-positive neoplastic cells present.
Treatment: Brentuximab Vedotin — This phase II trial studies how well brentuximab vedotin works in treating patients with CD30 positive (+) malignant mesothelioma that cannot be removed by surgery. Monoclonal antibodies, such as brentuximab vedotin, may interfere with the ability of tumor cells to grow and spread.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Mesothelioma
Biomarker criteria
Required: CD30 overexpression (positive immunohistochemical expression)
Positive CD30+ immunohistochemical expression
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: allogeneic bone marrow or organ transplantation
Prior allogeneic bone marrow or organ transplantation
Cannot have received: investigational drug
Patient has received other investigational drugs with 14 days before enrollment
Lab requirements
Blood counts
ANC > 1500/mm^3; Platelets > 100,000/mm^3; Hemoglobin > 8.5 g/dL
Kidney function
Calculated creatinine clearance must be ≥ 30 mL/minute
Liver function
Total bilirubin ≤ 1.5 x ULN; AST and ALT < 3 x ULN (≤ 5 x ULN if with known liver metastases)
ANC > 1500/mm^3; Platelets > 100,000/mm^3; Hemoglobin (Hgb) > 8.5 g/dL; Total bilirubin ≤ 1.5 x ULN; AST and ALT < 3 x ULN (≤ 5 x ULN if with known liver metastases); Calculated creatinine clearance must be ≥ 30 mL/minute
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03007030 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic bone marrow or organ transplantation, investigational drug disqualifies patients from enrollment.
Does this trial require CD30?
Yes, CD30 overexpression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages